← brief for 2026-10-22 · Slowing decline

Relative risk reduction is not enough: why cardiorenal trials should routinely report absolute risk reduction and number needed to treat.

Paper No results yet Peer reviewed

Key takeaways

This review argues that doctors should report the real-world benefit of heart and kidney drugs, not just the relative risk numbers. It is a discussion piece, not a new trial with results.

Who did this work

Zaitoon H · Abdul-Ghani M · DeFronzo RA

Source

Paper · PubMed, the drug frontier · 2026 Oct 12
https://pubmed.ncbi.nlm.nih.gov/42903819/